Get to know our clinical trials
Clinical trial of EOS884448 in combination with standard treatment and/or experimental therapies in participants with advanced solid tumors
THE MAIN OBJECTIVE OF PART 1G IS TO EVALUATE HOW WELL YOUR BODY TOLERATES THE STUDY TREATMENT (EOS-448 DOSTARLIMAB CHEMOTHERAPY) AND THE EFFICACY OF THE STUDY TREATMENT ON YOUR TUMOR. THE MAIN OBJECTIVE OF PARTS 2C AND 2D IS TO EVALUATE THE EFFICACY OF THE STUDY TREATMENT ON YOUR TUMOR AND HOW WELL YOUR BODY TOLERATES THE STUDY TREATMENT (EOS-448 DOSTARLIMAB). THE MAIN OBJECTIVE OF PART 2E IS TO EVALUATE THE EFFICACY OF THE STUDY TREATMENT ON YOUR TUMOR AND HOW WELL YOUR BODY TOLERATES THE STUDY TREATMENT (EOS-448 INUPADENANT). IN ADDITION, THE STUDY WILL EVALUATE WHAT HAPPENS TO THE STUDY TREATMENT AFTER ADMINISTRATION, HOW YOUR BODY GETS RID OF THE TREATMENT AND WHAT EFFECTS THE STUDY TREATMENT HAS ON YOUR BODY. THE EFFECTS OF THE STUDY TREATMENT WILL BE INVESTIGATED IN BLOOD SAMPLES AND TUMOR BIOPSIES AND BY MEASURING CHANGES IN TUMOR SIZE.
Technical Summary
- MULTICENTER, OPEN-LABEL, PHASE I/II STUDY OF EOS884448 IN COMBINATION WITH STANDARD TREATMENT AND/OR EXPERIMENTAL THERAPIES IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: 2021-001329-29
- Protocol number: TIG-006
- Promoter: iTeos Belgium SA
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.